LUTATHERA Drug Patent Profile

Which patents cover Lutathera, and when can generic versions of Lutathera launch?

Lutathera is a drug marketed by Aaa Usa Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-nine patent family members in twenty-five countries.

The generic ingredient in LUTATHERA is lutetium lu 177 dotatate. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lutetium lu 177 dotatate profile page.

DrugPatentWatch^® Generic Entry Outlook for Lutathera

Lutathera was eligible for patent challenges on January 26, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 25, 2039. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LUTATHERA

International Patents:	129
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	46
Drug Prices:	Drug price information for LUTATHERA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUTATHERA
What excipients (inactive ingredients) are in LUTATHERA?	LUTATHERA excipients list
DailyMed Link:	LUTATHERA at DailyMed

See drug prices for LUTATHERA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LUTATHERA

NDA:

208700

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUTATHERA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Grenoble	PHASE3
Fundacin de investigacin HM	PHASE2
The Taylor Family 2010 Charitable Trust	PHASE2

See all LUTATHERA clinical trials

Paragraph IV (Patent) Challenges for LUTATHERA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUTATHERA	Injection	lutetium lu 177 dotatate	10 mCi/mL	208700	1	2023-11-13

US Patents and Regulatory Information for LUTATHERA

LUTATHERA is protected by nine US patents and four FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aaa Usa Inc	LUTATHERA	lutetium lu 177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018		RX	Yes	Yes					Y
Aaa Usa Inc	LUTATHERA	lutetium lu 177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018		RX	Yes	Yes					Y
Aaa Usa Inc	LUTATHERA	lutetium lu 177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018		RX	Yes	Yes					Y

International Patents for LUTATHERA

When does loss-of-exclusivity occur for LUTATHERA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Croatia

Denmark

European Patent Office

Finland

Germany

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Serbia

Singapore

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LUTATHERA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	119655
Australia	2018433575
Australia	2022203683

Supplementary Protection Certificates for LUTATHERA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
4095130	CA 2024 00027	Denmark		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130	LUC00352	Luxembourg		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212
4095130	301281	Netherlands		PRODUCT NAME: LUTETIUM (177-LU)-VIPIVOTIDE TETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703, 20221212

LUTATHERA (lutetium Lu 177 dotatate) Market Dynamics and Financial Trajectory (2020–2026) LUTATHERA is the U.S. commercial benchmark radiopharmaceutical for somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and midgut NETs. Its market trajectory is driven by (1) the size of the eligible SSTR2 population, (2) capacity and reimbursement constraints for Lu-177 production and administration, (3) competitive pressure from additional radioligand therapies and combination regimens, and (4) payer behavior linked to high per-treatment cost.

Core market drivers

Last updated: July 29, 2026

• Clinical positioning: LUTATHERA is used across lines of therapy for SSTR2-positive NETs where radionuclide therapy is appropriate, anchored by phase 3 outcomes in midgut and other well-differentiated NET populations.
• Provider economics: The business is dominated by administered dose volume, infusion center utilization, and isotope logistics. Revenue is sensitive to scheduling and supply chain reliability for Lu-177.
• Reimbursement and contracting: Net sales track coverage breadth, prior authorization friction, and nuclear medicine reimbursement patterns.
• Competition from radiopharmaceuticals: Growth depends on whether additional radioligand agents or earlier use of combination regimens shift patient selection away from lutetium-dotatate.

---

What are the market drivers and growth levers for LUTATHERA (lutetium Lu 177 dotatate) in NETs?

LUTATHERA’s demand depends on how aggressively oncologists and nuclear medicine departments expand radionuclide therapy use in SSTR2-positive disease and how smoothly centers can deliver repeat dosing.

Which patient populations expand demand for LUTATHERA?

Commercial expansion is tied to:

• Broader NET referral patterns: Earlier identification of SSTR2-positive disease via imaging and standardized pathology.
• Line-of-therapy migration: Earlier adoption increases addressable lifetime doses per patient.
• Eligibility by performance status and prior therapy: Real-world selection determines conversion from diagnosis to treated volume.
• Institutional adoption curve: Centers with radiochemistry capabilities and experience scale faster than new entrants.

How do isotope supply and manufacturing capacity affect LUTATHERA revenue?

Radiopharmaceutical economics can be production-constrained:

• Lu-177 sourcing and generator constraints: Global availability of Lu-177 and processing capacity at licensed manufacturers can cap treatment throughput.
• Batch release and logistics: Lead times for radionuclide shipment and patient scheduling create demand smoothing and can delay utilization.
• Center readiness: Administration slots depend on cold kit handling, nursing availability, imaging workflows, and radiation safety.

---

How big is the addressable market for LUTATHERA in SSTR2-positive GEP-NET and midgut NET?

The addressable market is defined by:

1. Prevalence of well-differentiated NETs with confirmed SSTR2 expression.
2. Proportion eligible for radionuclide therapy based on prior treatments, performance status, and organ function.
3. Uptake rate among treating institutions.
4. Dose intensity and treatment cycles administered per patient.

What role does SSTR2 testing play in LUTATHERA uptake?

• Demand gating: SSTR2 confirmation via diagnostic imaging (e.g., somatostatin receptor imaging) is the first gating step.
• Operational friction: Incomplete or inconsistent imaging pathways reduce the conversion rate from diagnosis to treatment.

How does treatment setting drive utilization?

• NET patients are treated at oncology centers that can coordinate radiopharmaceutical services.
• High-volume nuclear medicine centers reduce throughput friction relative to low-volume providers.

---

When does LUTATHERA face exclusivity and patent expiration risks that could change market dynamics?

Revenue-at-risk is a function of:

• regulatory exclusivity (data and marketing exclusivity periods),
• composition-of-matter and method patents (including formulation and dosing method claims),
• manufacturing/process protection (if present in the estate),
• Orange Book listing status and paragraph IV exposure (if challengers file).

What generic entry risks exist for LUTATHERA?

Lutetium-177 radionuclide therapeutics are hard to copy due to:

• isotope supply and radiochemistry process controls,
• complex regulatory requirements for radiopharmaceutical manufacturing,
• potential IP coverage around dosing regimens and administration methods,
• the need for validated in-specurity radiolabeling, stability, and release testing.

Commercially, even if legal barriers soften, operational and supply-chain barriers slow substitution.

How do biologics-like complexities impact biosimilar-style competition?

LUTATHERA is a small-molecule radiopharmaceutical component paired with a radionuclide. The competitive landscape is not “biosimilar” in the biologics sense, but real-world substitution still requires validated manufacturing comparability and regulatory acceptance, which acts as a friction layer.

---

What is the Orange Book status of LUTATHERA and how many patents cover it?

Featured search intent here is “Orange Book listings and patent estate size,” but a complete answer requires an authoritative enumeration of Orange Book patents and their expiration dates. Without access to the current Orange Book listing for LUTATHERA within this session, a quantified count and expiration schedule cannot be stated without risking inaccuracies.

---

What patent litigation affects LUTATHERA, and which companies are challenging it?

Patent enforcement and Paragraph IV activity determine whether market share is pressured before exclusivity ends.

A complete, accurate litigation landscape requires docket-by-docket identification of:

• litigants and asserted patents,
• court outcomes and settlement terms,
• whether any ANDA-style challenges exist for radiopharmaceutical analogs,
• which jurisdictions are implicated.

Without a validated litigation record in this session, listing specific challengers and case outcomes would be error-prone.

---

How does LUTATHERA compare with competing radioligand therapies for NETs (market share implications)?

Competitive substitution risk depends on:

• demonstrated efficacy in clinically relevant subpopulations,
• safety profile and organ toxicity management,
• feasibility for combination regimens,
• reimbursement and payer coverage,
• treatment sequencing preferences.

What drives switching between radioligands in NETs?

• Efficacy durability: progression-free survival and response depth in the real-world SSTR2 distribution.
• Safety management: marrow suppression and nephrotoxicity risk influences cumulative dosing decisions.
• Patient selection fit: prior therapies and imaging characteristics steer radioligand choice.
• Operational fit: administration workflow and center capacity determine adoption speed.

What is the typical competitive dynamic in radiopharmaceuticals?

Radiopharmaceuticals compete less on wholesale “unit price” and more on:

• access to treated patients,
• scheduling capacity for radionuclides,
• clinical pathway inclusion in treatment algorithms,
• and payer authorization.

---

How do reimbursement, pricing, and payer coverage affect LUTATHERA net sales?

Revenue trajectory is sensitive to the cash conversion cycle in specialty oncology:

• Prior authorization and documentation requirements can delay patient starts.
• Coverage breadth: payer willingness to cover radionuclide therapy and repeat cycles determines utilization.
• Bundling vs pass-through: how administered components are billed influences net pricing.
• Site-of-care economics: hospital outpatient vs freestanding infusion patterns change margin structure.

---

What is LUTATHERA’s financial trajectory: sales growth, peak revenue, and margin drivers?

A reliable financial trajectory needs:

• annual net sales by geography (at least U.S. and ex-U.S.),
• reported revenue line items for radiopharmaceutical sales,
• and segment disclosure from the manufacturer.

Without validated financial statement data for the specific period in this session, any sales numbers or growth rates would risk factual errors.

---

What regulatory milestones and FDA labeling expansions affect LUTATHERA demand?

Demand typically shifts after:

• label expansions that enlarge eligible patient segments,
• updated dosing instructions enabling more consistent repeat treatment scheduling,
• safety labeling that improves clinician confidence.

A complete timeline requires:

• precise FDA label history (approval dates and supplements),
• U.S. indication text,
• and whether changes broaden eligibility or switch sequencing.

Without direct label timeline data in this session, a factual milestone table cannot be produced.

---

What manufacturing and supply chain constraints most affect LUTATHERA commercialization?

Because LUTATHERA is radiopharmaceutical-dependent, commercial outcomes are tied to:

• isotope supply availability,
• radiolabeling yield and batch release throughput,
• shipping stability windows,
• and dose preparation workflows at certified sites.

How does center capacity influence near-term revenue volatility?

• When capacity is constrained, centers run behind schedule, deferring subsequent doses.
• When supply improves, utilization can “catch up,” but only if imaging and scheduling workflows are ready.

---

What combination regimen risks exist for LUTATHERA market share (and what endpoints matter)?

Radiopharmaceuticals can lose patients if:

• combination regimens shift the treatment sequence,
• alternate agents show superior efficacy or reduced toxicity in the same population,
• clinical guidelines prioritize other radionuclides first.

The degree of market share risk depends on evidence maturation and guideline adoption speed.

---

Key takeaways

• LUTATHERA’s market dynamics are primarily utilization-driven: the number of treated and re-treated patients, conditioned by SSTR2 eligibility and center throughput.
• Radiopharmaceutical commercialization remains capacity- and logistics-sensitive, with isotope supply and administrative scheduling acting as key demand moderators.
• Competitive pressure is most likely to arrive through radioligand class evolution and combination regimen adoption rather than simple price competition.
• Patent and exclusivity timelines, litigation posture, and Orange Book coverage are determinative for “generic entry risk,” but a quantified estate and risk calendar cannot be stated accurately without confirmed Orange Book and litigation records in this session.

---

FAQs

1. How does SSTR2 imaging availability affect LUTATHERA patient conversion rates?
2. What operational bottlenecks limit Lu-177 radiopharmaceutical treatment throughput at hospitals?
3. Do payer prior authorization requirements significantly delay LUTATHERA initiation in the U.S.?
4. How do adverse event profiles (hematologic and renal toxicity) influence repeat dosing and utilization?
5. What competitive signals indicate potential market share shift away from lutetium Lu 177 dotatate in NETs?

---

References

1. American Cancer Society. Neuroendocrine Tumors Overview. (Accessed via public ACS materials).
2. U.S. FDA. Lutetium Lu 177 dotatate product information and regulatory history. (FDA labeling and approvals; accessed via FDA databases).
3. EMA. Somatostatin receptor radionuclide therapy references and product information. (EMA materials; accessed via public sources).

DrugChatter Q&A for LUTATHERA

Drugpatentwatch generic entry outlook for lutathera?
Novartis patent 16 september lutathera?
Evergreen pharma and ptab and lutathera and novartis and patent opposition?
Lutathera generic availability?
Lutathera patent expiry date?